Armata Pharmaceuticals (FRA:TG1N) Total Liabilities : €162.72 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Armata Pharmaceuticals Total Liabilities?

Armata Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was €162.72 Mil.

Armata Pharmaceuticals's quarterly Total Liabilities increased from Sep. 2023 (€117.26 Mil) to Dec. 2023 (€119.60 Mil) and increased from Dec. 2023 (€119.60 Mil) to Mar. 2024 (€162.72 Mil).

Armata Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 (€39.27 Mil) to Dec. 2022 (€56.41 Mil) and increased from Dec. 2022 (€56.41 Mil) to Dec. 2023 (€119.60 Mil).

Armata Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Armata Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Armata Pharmaceuticals Total Liabilities Chart

Armata Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

9.77

16.98

39.27

56.41

119.60

Armata Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															80.63	75.75	117.26	119.60	162.72

Armata Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Armata Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	15.095	+	(101.686	+	-0.0010000000000021
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	2.822	+	0)
	=	119.60

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	90.199	-	-29.404
	=	119.60

Armata Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	101.241	+	(58.644	+	0.001000000000015
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	2.831	+	0)
	=	162.72

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	110.728	-	-51.989
	=	162.72

Armata Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Armata Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Armata Pharmaceuticals (FRA:TG1N) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Armata Pharmaceuticals Inc (FRA:TG1N) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ARMP:USA TG1M:Germany

Address

4503 Glencoe Avenue, Marina del Rey, CA, USA, 90292

Website

https://www.armatapharma.com

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Armata Pharmaceuticals (FRA:TG1N) Headlines

No Headlines